Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels

AIDS

Volumn 29, Issue 8, 2015, Pages 911-919

  Cunningham, William J Hey ^a,b   Murray, John M ^c   Natarajan, Ven ^d   Amin, Janaki ^a   Moore, Cecilia L ^a   Emery, Sean ^a   Cooper, David A ^a,b   Zaunders, John ^a,b   Kelleher, Anthony D ^a,b   Koelsch, Kersten K ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

antiretroviral therapy; Decay; DNA; Early; HIV; Reservoirs; RNA

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE RESERVOIR; GENE DOSAGE; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; OPEN STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TREATMENT INTERRUPTION; VIRAL RNA BLOOD LEVEL; VIREMIA; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CROSS-SECTIONAL STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MULTICENTER STUDY; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DRUG THERAPY, COMBINATION; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; RALTEGRAVIR POTASSIUM; RNA, VIRAL; VIRAL LOAD;

EID: 85003049156     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000625     Document Type: Article

References (45)

1. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4R T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512 517.
2. Smith M, Wightman F, Lewin S. HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep 2012; 1:5 15.
3. Deeks SG, Verdin E, McCune JM. Immunosenescence and HIV. Curr Opin Immunol 2012; 4:501 506.
4. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-Term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4R T cells. Nat Med 2003; 6:727 728.
5. Chun T-W, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 1:135 138.
6. Cockerham LR, Siliciano JD, Sinclair E, O Doherty U, Palmer S, Yukl SA, et al. CD4Rand CD8RT cell activation are associated with HIV DNA in resting CD4R T cells. PLoS One 2014; 10:e110731.
7. Walker BD, Hirsch MS. Antiretroviral therapy in early HIV infection. N Engl J Med 2013; 3:279 281.
8. Anglemyer A, Rutherford GW, Easterbrook PJ, Horvath T, Vitó ria M, Jan M, et al. Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: A systematic review. AIDS 2014; 28:105 108.
9. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4R T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 15:8869.
10. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014; 512:74 77.
11. Strain MC, Little SJ, Daar ES, Havlir DV, Günthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-J Infect Dis 2005; 9:1410.
12. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, et al. Impact of multi-Targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 3:e33948.
13. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010; 25:5571 5579.
14. Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A, et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 15:2049 2054.
15. Okulicz JF, Le TD, Agan BK, et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1 infected individuals. JAMA Intern Med 2014; 175:88 89.
16. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208:1202 1211.
17. Hatano H, Jain V, Hunt PW, Lee T-H, Sinclair E, Do TD, et al. Cell-based measures of viral persistence are associated with immune activation and PD-1 expressing CD4R T cells. J Infect Dis 2012; 208:50 56.
18. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 6629:183 188.
19. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 2:e1003174.
20. Ho Y-C, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 3:540 551.
21. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 4:460 465.
22. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, et al. Increase in 2 long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: A randomized, placebo-controlled trial. J Infect Dis 2013; 9:1436 1442.
23. Besson GJ, McMahon D, Maldarelli F, Mellors JW. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis 2012; 54:451 453.
24. Pace MJ, Graf EH, O Doherty U. HIV 2-long terminal repeat circular DNA is stable in primary CD4RT Cells. Virology 2013; 1:18 21.
25. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002; 8:4138 4144.
26. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005; 8:5203.
27. Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, et al. HIV DNA subspecies persist in both activated and resting memory CD4R T cells during antiretroviral therapy. J Virol 2014; 6:3516 3526.
28. Murray JM, McBride K, Boesecke C, Bailey M, Amin J, Suzuki K, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 2012; 5:543 550.
29. Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, et al. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 2011; 17:2069 2078 10.1097/QAD.0b013e32834b9658.
30. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JAM, Polis M, et al. New real-Time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 10:4531.
31. Brussel A, Mathez D, Broche-Pierre S, Lancar R, Calvez T, Sonigo P, et al. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 2003; 5:645 652.
32. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 8:893 900.
33. Zaunders JJ, Munier ML, Kaufmann DE, Ip S, Grey P, Smith D, et al. Early proliferation of CCR5RCD38RRRantigen-specific CD4RTh1 effector cells during primary HIV-1 infection. Blood 2005; 5:1660 1667.
34. World Health Organization. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. www.who.int/hiv/pub/guidelines/arv2013/.
35. Hocqueloux L, Avettand-Fenoel V, Jacquot S, Prazuck T, Legac E, Melard A, et al. Long-Term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; 5:1169 1178.
36. Williams JP, Hurst J, Stohr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA predicts disease progression and posttreatment virological control. Elife 2014; 10:e03821.
37. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-Treatment HIV-1 controllers with a long-Term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 2013; 3:e1003211.
38. Shah SK, Persaud D, Wendler DS, Taylor HA, Gay H, Kruger M, et al. Research into a functional cure for HIV in neonates: The need for ethical foresight. Lancet Infect Dis 2014; 14:893 898.
39. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee T-H, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation report of 2 cases HIV-1 remission and viral rebound after allogeneic HSCT. Ann Intern Med 2014; 5:319 327.
40. Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T cell activation. J Acquir immune Defic Syndr 2013; 62:505 508.
41. Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, et al. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8R T-cell activation. Antivir Ther 2007; 12:971 975.
42. Poizot-Martin I, Faucher O, Obry-Roguet V, Nicolino-Brunet C, Ronot-Bregigeon S, Dignat-George F, et al. Lack of correlation between the size of HIV proviralDNAreservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J Clin Virol 2013; 4:351 355.
43. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 10:e203.
44. Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, et al. Long-Term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 2014; 17:10056 10065.
45. Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis 2014; 59:1312 1321